Synopsis
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - 0.25%
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.25%;0.0091M...DOSAGE - INJECTABLE;INJECTION - 0.25%;0.0091MG/ML
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.5%
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG...DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG/ML
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.75%
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.75%;0.0091M...DOSAGE - INJECTABLE;INJECTION - 0.75%;0.0091MG/ML
USFDA APPLICATION NUMBER - 16964
DOSAGE - INJECTABLE;INJECTION - 0.25%
USFDA APPLICATION NUMBER - 18304
DOSAGE - INJECTABLE;INJECTION - 0.5%
USFDA APPLICATION NUMBER - 18304
DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG...DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG/ML
USFDA APPLICATION NUMBER - 18304
DOSAGE - INJECTABLE;INJECTION - 0.75%
USFDA APPLICATION NUMBER - 18304
DOSAGE - INJECTABLE;INJECTION - 0.75%;0.0091M...DOSAGE - INJECTABLE;INJECTION - 0.75%;0.0091MG/ML
USFDA APPLICATION NUMBER - 18304
DOSAGE - INJECTABLE;INJECTION - 4%; EQ 0.0085...DOSAGE - INJECTABLE;INJECTION - 4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)
USFDA APPLICATION NUMBER - 20971
DOSAGE - INJECTABLE;INJECTION - 4%;EQ 0.017MG...DOSAGE - INJECTABLE;INJECTION - 4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)
USFDA APPLICATION NUMBER - 20971
DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG...DOSAGE - INJECTABLE;INJECTION - 0.5%;0.0091MG/ML
USFDA APPLICATION NUMBER - 22046
DOSAGE - INJECTABLE;INJECTION - EQ 0.02MG BAS...DOSAGE - INJECTABLE;INJECTION - EQ 0.02MG BASE/ML;2%
USFDA APPLICATION NUMBER - 88389
DOSAGE - INJECTABLE;INJECTION - EQ 0.01MG BAS...DOSAGE - INJECTABLE;INJECTION - EQ 0.01MG BASE/ML;2%
USFDA APPLICATION NUMBER - 88390
Related Excipient Companies
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
47
PharmaCompass offers a list of Epinephrine Bitartrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Epinephrine Bitartrate manufacturer or Epinephrine Bitartrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Epinephrine Bitartrate manufacturer or Epinephrine Bitartrate supplier.
PharmaCompass also assists you with knowing the Epinephrine Bitartrate API Price utilized in the formulation of products. Epinephrine Bitartrate API Price is not always fixed or binding as the Epinephrine Bitartrate Price is obtained through a variety of data sources. The Epinephrine Bitartrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A LIGNOSPAN FORTE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of LIGNOSPAN FORTE, including repackagers and relabelers. The FDA regulates LIGNOSPAN FORTE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. LIGNOSPAN FORTE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of LIGNOSPAN FORTE manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A LIGNOSPAN FORTE supplier is an individual or a company that provides LIGNOSPAN FORTE active pharmaceutical ingredient (API) or LIGNOSPAN FORTE finished formulations upon request. The LIGNOSPAN FORTE suppliers may include LIGNOSPAN FORTE API manufacturers, exporters, distributors and traders.
click here to find a list of LIGNOSPAN FORTE suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A LIGNOSPAN FORTE DMF (Drug Master File) is a document detailing the whole manufacturing process of LIGNOSPAN FORTE active pharmaceutical ingredient (API) in detail. Different forms of LIGNOSPAN FORTE DMFs exist exist since differing nations have different regulations, such as LIGNOSPAN FORTE USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A LIGNOSPAN FORTE DMF submitted to regulatory agencies in the US is known as a USDMF. LIGNOSPAN FORTE USDMF includes data on LIGNOSPAN FORTE's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The LIGNOSPAN FORTE USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of LIGNOSPAN FORTE suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The LIGNOSPAN FORTE Drug Master File in Japan (LIGNOSPAN FORTE JDMF) empowers LIGNOSPAN FORTE API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the LIGNOSPAN FORTE JDMF during the approval evaluation for pharmaceutical products. At the time of LIGNOSPAN FORTE JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of LIGNOSPAN FORTE suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a LIGNOSPAN FORTE Drug Master File in Korea (LIGNOSPAN FORTE KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of LIGNOSPAN FORTE. The MFDS reviews the LIGNOSPAN FORTE KDMF as part of the drug registration process and uses the information provided in the LIGNOSPAN FORTE KDMF to evaluate the safety and efficacy of the drug.
After submitting a LIGNOSPAN FORTE KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their LIGNOSPAN FORTE API can apply through the Korea Drug Master File (KDMF).
click here to find a list of LIGNOSPAN FORTE suppliers with KDMF on PharmaCompass.
A LIGNOSPAN FORTE CEP of the European Pharmacopoeia monograph is often referred to as a LIGNOSPAN FORTE Certificate of Suitability (COS). The purpose of a LIGNOSPAN FORTE CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of LIGNOSPAN FORTE EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of LIGNOSPAN FORTE to their clients by showing that a LIGNOSPAN FORTE CEP has been issued for it. The manufacturer submits a LIGNOSPAN FORTE CEP (COS) as part of the market authorization procedure, and it takes on the role of a LIGNOSPAN FORTE CEP holder for the record. Additionally, the data presented in the LIGNOSPAN FORTE CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the LIGNOSPAN FORTE DMF.
A LIGNOSPAN FORTE CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. LIGNOSPAN FORTE CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of LIGNOSPAN FORTE suppliers with CEP (COS) on PharmaCompass.
A LIGNOSPAN FORTE written confirmation (LIGNOSPAN FORTE WC) is an official document issued by a regulatory agency to a LIGNOSPAN FORTE manufacturer, verifying that the manufacturing facility of a LIGNOSPAN FORTE active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting LIGNOSPAN FORTE APIs or LIGNOSPAN FORTE finished pharmaceutical products to another nation, regulatory agencies frequently require a LIGNOSPAN FORTE WC (written confirmation) as part of the regulatory process.
click here to find a list of LIGNOSPAN FORTE suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing LIGNOSPAN FORTE as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for LIGNOSPAN FORTE API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture LIGNOSPAN FORTE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain LIGNOSPAN FORTE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a LIGNOSPAN FORTE NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of LIGNOSPAN FORTE suppliers with NDC on PharmaCompass.
LIGNOSPAN FORTE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of LIGNOSPAN FORTE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right LIGNOSPAN FORTE GMP manufacturer or LIGNOSPAN FORTE GMP API supplier for your needs.
A LIGNOSPAN FORTE CoA (Certificate of Analysis) is a formal document that attests to LIGNOSPAN FORTE's compliance with LIGNOSPAN FORTE specifications and serves as a tool for batch-level quality control.
LIGNOSPAN FORTE CoA mostly includes findings from lab analyses of a specific batch. For each LIGNOSPAN FORTE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
LIGNOSPAN FORTE may be tested according to a variety of international standards, such as European Pharmacopoeia (LIGNOSPAN FORTE EP), LIGNOSPAN FORTE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (LIGNOSPAN FORTE USP).
